Advancements in corneal collagen cross-linking have significantly reduced the number of children who require a corneal ...
The ongoing opioid epidemic highlights health care’s role in fueling the crisis as well as the highly addictive nature of ...
SHERBORN, Mass.--(BUSINESS WIRE)--CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, today published results of the EpiSmart cross-linking Phase ...
-- Study did not meet primary endpoint of complete healing of PCED at Week 8; secondary endpoints also did not achieve statistical significance -- -- KPI-012 was well-tolerated with no ...
On Monday, Glaukos Corporation (NYSE:GKOS) received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for ...
Glaukos (GKOS) announced the submission of its New Drug Application NDA to the U.S. Food and Drug Administration FDA or Epioxa or Epi-on, its next-generation corneal cross-linking iLink therapy for ...
Corneal defects often heal themselves, but serious injuries that are left untreated can result in inflammation, infection, ulceration and even blindness. A new study provides exciting evidence ...
The US Food and Drug Administration (FDA) has approved Glaukos Corporation’s Epioxa, offering patients living with a rare corneal disease a treatment option that does not require incisions. Epioxa, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results